Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products.

Seminars in thrombosis and hemostasis - 1 Jun 2002

Kreuz Wolfhart, Ettingshausen Carmen Escuriola, Zyschka Alex, Oldenburg Johannes, Saguer Inmaculada Martinez, Ehrenforth Silke, Klingebiel Thomas

Abstract excerpt

In order to assess inhibitor development in previously untreated patients (PUPs) with severe (factor VIII [FVIII]<1%) and moderate (FVIII 1 to 5%) hemophilia A, a prospective study was initiated in 1976. During the 23-year study period, 72 hemophiliacs were frequently exposed prophylactically or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoantibodies
Share to Cohort Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Factor VIII

Share to Follow-Up Studies

Share to Hemophilia A

Share to Hemophilia B

Share to Recombinant Proteins

Source

Identifiers

PMID: 12098090
DOI: 10.1055/s-2002-32664

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-12098090-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products.PMID 12098090Read ↗

Incidence of inhibitors in haemophilia A patients – a review of recent studies of recombinant and plasma‐derived factor VIII concentratesSemantic proximity Read ↗

Inhibitor development in previously untreated patients with severe haemophilia A: a nationwide multicentre study in Finland.Semantic proximity Read ↗

Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010.Semantic proximity Read ↗

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.Semantic proximity Read ↗

Risk factors for high-titer inhibitor development in children with hemophilia A: results of a cohort study.Semantic proximity Read ↗

Improved prediction of inhibitor development in previously untreated patients with severe haemophilia A.Semantic proximity Read ↗

Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies.Semantic proximity Read ↗

In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study.Semantic proximity Read ↗

Inhibitors in the Swedish population with severe haemophilia A and B: a 20-year survey.Semantic proximity Read ↗

Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis.Semantic proximity Read ↗

Inhibitor development: patient-determined risk factors.Semantic proximity Read ↗

Treatment related factors and inhibitor development in children with severe haemophilia A.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.